Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asunercept - Apogenix

Drug Profile

Asunercept - Apogenix

Alternative Names: APG-101; Apocept; Asinercept; CAN-008

Latest Information Update: 14 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apogenix
  • Developer Apogenix; CANbridge Pharmaceuticals; University Hospital Heidelberg
  • Class Antineoplastics; Antivirals; Eye disorder therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Apoptosis inhibitors; Fas ligand protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Myelodysplastic syndromes; Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioblastoma; Myelodysplastic syndromes

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase I Skin disorders
  • Preclinical Eye disorders
  • No development reported Graft-versus-host disease; Myelodysplastic syndromes; Myocardial infarction; Solid tumours; Stroke
  • Discontinued Glioblastoma

Most Recent Events

  • 14 Jun 2024 Asunercept is no longer licensed to CANbridge prior to June 2024 (Apogenix pipeline, June 2024)
  • 14 Jun 2024 Discontinued - Phase-I/II for Glioblastoma (Combination therapy, Newly diagnosed) in Taiwan (IV) prior to June 2024 (Aapogenix pipeline, June 2024)
  • 14 Jun 2024 Discontinued - Phase-I/II for Glioblastoma (Newly diagnosed) in Germany (IV) prior to June 2024 (Aapogenix pipeline, June 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top